STRS Ohio’s Design Therapeutics DSGN Stock Holding History

STRS Ohio’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$731K	Buy	50,500 +5,800	+13%	+$72.3K	﹤0.01%	906
2026 Q1	$476K	Buy	44,700 +19,500	+77%	+$197K	﹤0.01%	1107
2025 Q4	$236K	Buy	25,200 +2,600	+12%	+$20.4K	﹤0.01%	1450
2025 Q3	$170K	Hold	22,600	–	–	﹤0.01%	1618
2025 Q2	$76.2K	Hold	22,600	–	–	﹤0.01%	1944
2025 Q1	$87.2K	Sell	22,600 -10,000	-31%	-$47.7K	﹤0.01%	1694
2024 Q4	$201K	Hold	32,600	–	–	﹤0.01%	1510
2024 Q3	$175K	Hold	32,600	–	–	﹤0.01%	1593
2024 Q2	$109K	Buy	32,600 +3,300	+11%	+$12.9K	﹤0.01%	1684
2024 Q1	$118K	Sell	29,300 -43,500	-60%	-$116K	﹤0.01%	1656
2023 Q4	$192K	Hold	72,800	–	–	﹤0.01%	1573
2023 Q3	$171K	Buy	+72,800	New	+$340K	﹤0.01%	1601
2021 Q4	–	Sell	-2,000	Closed	-$29K	–	2222
2021 Q3	$29K	Sell	2,000 -1,100	-35%	-$18.3K	﹤0.01%	2146
2021 Q2	$61K	Buy	+3,100	New	+$78.2K	﹤0.01%	2073

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

STRS Ohio's DSGN Position: Q2 2026 in Review

STRS Ohio increased its Design Therapeutics (DSGN) stake by 13% in Q2 2026, buying an estimated $72.3K and bringing the position to 50,500 shares worth $731K. The position accounts for ﹤0.01% of the portfolio, ranked #906.

STRS Ohio first reported a position in DSGN in Q2 2021 and has held it in 14 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

STRS Ohio held 50,500 shares of Design Therapeutics worth $731K as of Q2 2026.
STRS Ohio bought 5,800 Design Therapeutics shares in Q2 2026, an estimated $72.3K.
Design Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #906 holding.
STRS Ohio first reported a position in Design Therapeutics in Q2 2021 and has held it in 14 quarters since.
137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.